{
    "clinical_study": {
        "@rank": "16824", 
        "arm_group": [
            {
                "arm_group_label": "Scopolamine", 
                "arm_group_type": "Experimental", 
                "description": "0.2 mg intranasal scopolamine"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "0.1 mg intranasal"
            }
        ], 
        "brief_summary": {
            "textblock": "Part 1, the pharmacokinetic (PK) phase, will expand upon the pilot study conducted at Naval\n      Medical Research Laboratory (NAMRL) and has the goal of determining bioavailability and time\n      to Cmax in a larger representative sample. Part 2, the efficacy phase, is to determine the\n      efficacy of the aqueous spray solution via exposure to a nausea-inducing stimulus."
        }, 
        "brief_title": "Pharmacokinetic and Efficacy Profile Intranasal Scopolamine Spray", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Motion Sickness", 
        "condition_browse": {
            "mesh_term": "Motion Sickness"
        }, 
        "detailed_description": {
            "textblock": "Part 1: The pharmacokinetic (PK) phase Objective: To determine the bioavailability and\n      amount of scopolamine absorbed after administration of 0.2 mg intranasal scopolamine at\n      regular intervals across 8 hours post- dose.\n\n      Hypothesis: Detectable levels of Intranasal scopolamine (INSCOP) will be present in subject\n      plasma within 15 minutes post-dose; mean time to Cmax (maximum plasma concentration) will be\n      less than 1.5 hr.\n\n      Part 2: The Efficacy phase Objective: To determine the effectiveness, cognitive performance\n      effects, and medication side-effect profile of 0.2 mg intranasal scopolamine spray as a\n      motion sickness (MS) countermeasure.\n\n      Hypothesis: The primary hypothesis is that the INSCOP spray will be more efficacious against\n      MS than placebo, without statistically significant cognitive performance side-effects.\n      Specifically, participants will tolerate significantly more provocative head tilts in the\n      INSCOP condition than in the placebo condition."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males and females, 18 to 39 years old, inclusive, in good general health as\n             determined by physical examination and without clinically significant laboratory\n             profiles\n\n          -  Normal weight for body size, based on Physical Readiness Test Body Composition\n             Assessment (PPRTBCA) table\n\n          -  Willing and able to comply with study requirements and restrictions; and read and\n             sign the informed consent.\n\n        Exclusion Criteria:\n\n          -  Known and/or documented drug allergies, especially to scopolamine\n\n          -  Use of an investigational drug within 30 days of starting the study\n\n          -  Smoking or use of tobacco products, including \"chew\" or \"snuff\", within six months\n\n          -  Blood donation or significant blood loss within 30 days of starting the study\n\n          -  Significant gastrointestinal disorder, asthma, or seizure disorders\n\n          -  History of narrow-angle glaucoma\n\n          -  History of urinary retention problems\n\n          -  History of alcohol or other drug abuse\n\n          -  Pregnancy or suspected pregnancy, or lactation\n\n          -  Hematocrit values less than 41% for males and 37% for females\n\n          -  Recent nasal, nasal sinus or nasal mucosa surgery\n\n          -  Use of prescription, over-the-counter, or herbal medication in past 7 days"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "39 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02155309", 
            "org_study_id": "NAMRUD.2013.0004"
        }, 
        "intervention": {
            "arm_group_label": [
                "Scopolamine", 
                "Placebo"
            ], 
            "intervention_name": "Scopolamine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Scopolamine", 
                "Butylscopolammonium Bromide"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "scopolamine", 
            "motion", 
            "sickness"
        ], 
        "lastchanged_date": "June 2, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Dayton", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "45433"
                }, 
                "name": "Naval Medical Research Unit"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Pharmacokinetic and Efficacy Profile of Low-Dose Intranasal Scopolamine Spray for Motion Sickness", 
        "overall_official": {
            "affiliation": "Naval Medical Research Unit - Dayton", 
            "last_name": "Willliam J Becker, Phd", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of head movements", 
            "safety_issue": "No", 
            "time_frame": "40 min"
        }, 
        "reference": {
            "PMID": "11297908", 
            "citation": "Kl\u00f6cker N, Hanschke W, Toussaint S, Verse T. Scopolamine nasal spray in motion sickness: a randomised, controlled, and crossover study for the comparison of two scopolamine nasal sprays with oral dimenhydrinate and placebo. Eur J Pharm Sci. 2001 May;13(2):227-32. PubMed"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02155309"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Epiomed Therapeutics, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Epiomed Therapeutics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}